Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

Item
http://www.wikidata.org/entity/Q27010014
GLP-1-based strategies: a physiological analysis of differential mode of actionEffects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysisLaboratory animals as surrogate models of human obesity.Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway.Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus.Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism.Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.Experience with the high-intensity sweetener saccharin impairs glucose homeostasis and GLP-1 release in rats.A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification.Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study.Efficacy of laparoscopic sleeve gastrectomy and intensive medical management in obese patients with type 2 diabetes mellitus.Equine glucagon-like peptide-1 receptor physiology.Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophySafety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios
P2860

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system

Item
http://www.wikidata.org/entity/Q27010014
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Beyond glucose lowering: gluca ...... and the cardiovascular system
@ast
Beyond glucose lowering: gluca ...... and the cardiovascular system
@en
Beyond glucose lowering: gluca ...... and the cardiovascular system
@nl
type
label
Beyond glucose lowering: gluca ...... and the cardiovascular system
@ast
Beyond glucose lowering: gluca ...... and the cardiovascular system
@en
Beyond glucose lowering: gluca ...... and the cardiovascular system
@nl
prefLabel
Beyond glucose lowering: gluca ...... and the cardiovascular system
@ast
Beyond glucose lowering: gluca ...... and the cardiovascular system
@en
Beyond glucose lowering: gluca ...... and the cardiovascular system
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Beyond glucose lowering: gluca ...... and the cardiovascular system
@en
P2093
P304
P31
P356
10.1016/J.DIABET.2011.07.001
P407
P433
P478
P577
P698
P921